Wealthcare Advisory Partners’s abrdn Life Sciences Investors HQL Stock Holding History

Wealthcare Advisory Partners’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$229K	Buy	12,252 +376	+3%	+$7.6K	﹤0.01%	1004
2026 Q2	$238K	Buy	11,876 +361	+3%	+$6.38K	﹤0.01%	972
2026 Q1	$187K	Buy	11,515 +702	+6%	+$11.7K	﹤0.01%	1028
2025 Q4	$181K	Hold	10,813	–	–	﹤0.01%	1029
2025 Q3	$168K	Buy	10,813 +316	+3%	+$4.33K	﹤0.01%	982
2025 Q2	$134K	Buy	10,497 +196	+2%	+$2.42K	﹤0.01%	946
2025 Q1	$131K	Buy	+10,301	New	+$139K	﹤0.01%	882

Other funds holding HQL

PMG Family Office Plano, Texas $108M AUM 8.93% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.95B AUM 25.45% 1-Year Est. Return

Decision Investments San Diego, California $110M AUM 52.83% 1-Year Est. Return

Independent Financial Group San Diego, California $5.51B AUM 33.51% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Private Trust Company Cleveland, Ohio $1.27B AUM 20.99% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Highline Wealth Partners Sherman Oaks, California $527M AUM 13.86% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

Wealthcare Advisory Partners's HQL Position: Q3 2026 in Review

Wealthcare Advisory Partners increased its abrdn Life Sciences Investors (HQL) stake by 3.2% in Q3 2026, buying an estimated $7.6K and bringing the position to 12,252 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #1004.

Wealthcare Advisory Partners first reported a position in HQL in Q1 2025 and has held it in 7 quarters since. The position peaked at $238K in Q2 2026. 11 funds tracked by Wall St. Rank hold HQL as of Q3 2026.

Wealthcare Advisory Partners held 12,252 shares of abrdn Life Sciences Investors worth $229K as of Q3 2026.
Wealthcare Advisory Partners bought 376 abrdn Life Sciences Investors shares in Q3 2026, an estimated $7.6K.
abrdn Life Sciences Investors made up ﹤0.01% of Wealthcare Advisory Partners's portfolio in Q3 2026, its #1004 holding.
Wealthcare Advisory Partners first reported a position in abrdn Life Sciences Investors in Q1 2025 and has held it in 7 quarters since.
Wealthcare Advisory Partners's abrdn Life Sciences Investors position peaked at $238K in Q2 2026.
11 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2026.

Based on Wealthcare Advisory Partners's 13F filing for Q3 2026, filed 21 Oct 2026.